ULTI.OL
Ultimovacs ASA [ULTI.OL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ULTI.OL Stock Summary
In the News
ULTI.OL Financial details
Company Rating
-
Market Cap
342.93M
Income
-172.59M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
24
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-28.72
Forward P/E
-
PEG
-16.88
P/S
-
P/B
14.87
P/C
-
P/FCF
-24.62
Quick Ratio
6.51
Current Ratio
6.81
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.02
EPS next Y
-
EPS next Q
-
EPS this Y
28.21%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
0.62%
-
-
-
-
SMA20
320.61%
SMA50
350.23%
SMA100
441.81%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-43%
ROC
-0.67%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
6.07-178.6
52W High
-98.96%
52W Low
-69.17%
RSI
42.59
Rel Volume
0.01
Avg Volume
1.4M
Volume
12.87K
Perf Week
-6.09%
Perf Month
-13.95%
Perf Quarter
-
Perf Half Y
1.09%
-
-
-
-
Beta
1.007
-
-
Volatility
8.51%, 5.78%
Prev Close
-90%
Price
1.85
Change
-90.84%
Company Profile
- Volume Average 1.4M
- Market Capitalization 342.93M
- Employee 24
- CEO Dr. Carlos de Sousa
- Headquarters Oslo,NO
- IPO Date 2019-06-03
-
Website
https://ultimovacs.com 
Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
